HOME >> BIOLOGY >> NEWS
Microscopic miracles

"Nanotechnology" is a newly fashionable field but in the world of drug development it is certainly not new, Professor Ruth Duncan of the Welsh School of Pharmacy, Cardiff University has told the British Pharmaceutical Conference (September 27-29).

The first nanomedicines are already bringing clinical benefit to thousands of patients, said Professor Duncan in her Conference Science Chairman's address.

"Progress in the development of nano-sized hybrid therapeutics and nano-sized drug delivery systems over the last decade has been remarkable. A growing number of products have already secured regulatory authority approval and, in turn, are supported by a healthy clinical development pipeline. They include products used to treat multiple sclerosis, AIDS, cancer, hepatitis and arthritis."

Furthermore, the improved understanding of the molecular basis of disease has led to "real optimism that a new generation of improved medicines is just around the corner," Professor Duncan said.

New drugs and new delivery systems both come under the "nanomedicine" umbrella. Drug delivery systems are needed to exploit many of the drugs developed from advances in molecular biology. Professor Duncan said: "The challenge is to design innovative devices and technologies able to guide the therapeutic to its correct location of action and ensure that pharmacological activity is maintained for an adequate duration once there."

Professor Duncan's research (funded by CRC, now Cancer Research UK) led to the transfer of the first polymer-based anticancer conjugates into clinical trial. She pointed out that polymer therapeutics -- which was unfashionable and considered an eccentricity in the 1970s and 80s -- had now generated promising compounds in many disease areas.

Looking to the future, Professor Duncan said that nanomedicine research is expected to bring significant advances in the diagnosis and treatment of disease.

She said: "Thi
'"/>

Contact: Professor Ruth Duncan
CPTOFFICE@cf.ac.uk
44-292-087-6419
Cardiff University
28-Sep-2004


Page: 1 2

Related biology news :

1. Microscopic bone evidence supports dinosaur-bird evolution link
2. Researchers Corral Millions Of Microscopic Membranes
3. UC Berkeley, U.S.G.S. Scientists Discover Microscopic Invader Of San Francisco Bay, The First Known Marine Microbe Invader Of U.S. Waters

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... ... today announced that an extensive third-party assessment of the company’s security practices has ... measured against federal security regulations. The comprehensive evaluation reviewed Litmus’ processes and systems, ...
(Date:8/26/2020)... ... August 25, 2020 , ... ... solutions for drugs, biologics, cell and gene therapies, and consumer health products, today ... PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – September ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien ... announced that the U.S. Food and Drug Administration (FDA) has approved the company’s ... for the treatment of severe COVID-19. Approval of this IND allows Sentien to ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... Slone ... companies, has announced the placement of Julianne Averill , CPA, as Chief ... all financial operations and implementing key business strategies to accelerate Alveo’s growth as ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... is making available for free its new white paper – Simulated Transport ... testing into today’s biologics licensing application (BLA). In response, Modality Solutions shares ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... 2020 , ... eSource has long been touted as the solution to high ... eSource, the reasons it did not take off as quickly as people initially expected, ... is moving towards capturing data electronically for clinical trials and then repurposing it for ...
Breaking Biology Technology:
Cached News: